Navigation Links
BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine

ket acceptance, the success of clinical testing, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which discussions also are incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact

BioSante Pharmaceuticals, Inc.
Phillip Donenberg, (847) 478-0500
donenber@biosantepharma.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
3. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
4. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
5. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
...  The Center for World Health & Medicine at Saint ... (GIBH) are forming a global research partnership that initially will ... are not only connected by a shared commitment to fight ... Inc. drug discovery scientists who formerly worked together in Chesterfield, ...
... 18, 2011 CVS Caremark (NYSE: CVS ... (PBMI) awarded the company and its PBM client ArcelorMittal, ... Innovation Award.  The award recognizes the Pharmacy Advisor program, ... improve medication adherence and close gaps in care for ...
Cached Medicine Technology:Saint Louis U Scientists Partner on Malaria Research 2Saint Louis U Scientists Partner on Malaria Research 3CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for Pharmacy Advisor Program 2CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for Pharmacy Advisor Program 3
(Date:8/31/2015)... ... 2015 , ... On Saturday, May 30th, 2015, Best Drug Rehabilitation sponsored a ... Mendon, IL. The purpose behind this concert was to raise money for music education ... Drug Rehabilitation’s sponsorship of “Music with a Mission” helped with a portion of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While working as an ... effectively deliver oxygen with a lower risk of failure," explained an inventor, from ... the Adam Device." , The Adam Device offers a quick, effective and predictable ...
(Date:8/31/2015)... ... August 31, 2015 , ... Westchester ... Grand Prairie, is teaming up with the Tarrant County chapter of Meals on ... on Wheels is the oldest and largest national organization that supports the more ...
(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like coming home. Life-long ... of Geneva. During his first days on the job, he’s run into residents of ... and I like knowing that they’re living in such a wonderful place,” he said. ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Now here’s some ... advice to "make at least half your grains whole,” with the majority of Americans ... Oldways Whole Grains Council (WGC) released these findings and others from the ...
Breaking Medicine News(10 mins):Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5
... a one in eight lifetime risk that a woman will ... remains early detection. Now, Women & infants Hospital of Rhode ... level with the installation of the most advanced imaging technology ... the first and only facility in southeastern New England to ...
... effort to replace animal fat in hot dogs, sausages, hamburgers ... advance in solving the mystery of why hot dogs develop ... animal fat. A report on their study appears in ACS, ... M. Herrero and colleagues explain that some brands of sausage ...
... proven the continuing effectiveness of treating patients with ... acid in addition to adjuvant endocrine treatment including ... Austrian Breast & Colorectal Cancer Study Group (ABCSG-12), ... Cancer Symposium, held Dec. 6-10, 2011, confirmed and ...
... waves, could stop many victims of major head injury from ... Neurology has found. Scientists have been investigating ... now of keen interest to the U.S. military because head ... in Iraq and Afghanistan. Researchers at King,s College London ...
... 2011 A research team led by scientists at the Chinese ... how a bacterium, Helicobacter pylori , that causes more than ... stomach cancer has managed for eons to turn the acidic environment ... Writing in a Journal of Biological Chemistry "Paper ...
... Post-menopausal women with hormone receptor-positive metastatic breast cancer ... their lives, according to results of a study by ... the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. ... fulvestrant used in the SWOG S0226 trial extended the ...
Cached Medicine News:Health News:Hospital gives first tomosynthesis mammograms in region this week 2Health News:Zoledronic acid shows long-term benefit in survivorship for premenopausal ER-positive breast cancer 2Health News:Brain tsunamis' are clue to helping victims of major head injuries 2Health News:Brain tsunamis' are clue to helping victims of major head injuries 3Health News:Closing in on an ulcer- and cancer-causing bacterium 2Health News:Closing in on an ulcer- and cancer-causing bacterium 3Health News:Anti-estrogen combo better than single drug for hormone-sensitive breast cancer 2
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
... Normal and Abnormal ... Assays of vWF, D-dimer ... on STA© Analyzers. For ... vWF (#0518),STA© LIATEST© D-DI ...
CRP high sensitivity calibrator series...
Inquire...
Medicine Products: